Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 56 IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PLASMA-LYTE 56 is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and electrolyte balance. It expands extracellular fluid volume and improves circulation by increasing plasma volume. The solution's electrolyte composition mimics plasma, helping to correct electrolyte deficits and acid-base disturbances.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Intravenous administration for fluid and electrolyte replacement in patients with deficits of water and electrolytes,Maintenance of fluid and electrolyte balance when oral intake is inadequate,Treatment of hypovolemia (low blood volume) due to various causes such as dehydration, burns, or surgery
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous infusion; dose depends on fluid and electrolyte needs; typical adult rate: 100-200 m L/hour.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Not applicable as a fixed value; infused electrolytes distribute and are eliminated according to individual ion kinetics (e.g., sodium t½ ~30 min, chloride t½ ~1–2 h) with rapid redistribution.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
PLASMA-LYTE 56 is a crystalloid solution; its components are not metabolized. Electrolytes are distributed and eliminated via renal excretion and normal physiological pathways. The solution itself is not subject to hepatic metabolism.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Primarily renal; >90% of infused electrolytes are excreted unchanged in urine; fecal elimination negligible (<5%).
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Minimal (<5%); electrolytes (Na+, Cl-, K+, Mg2+, acetate, gluconate) are not significantly protein-bound.
Negligible for electrolytes and dextrose (<5%).
Approximately 0.2–0.3 L/kg for sodium and chloride, corresponding to extracellular fluid volume; distributed throughout ECF.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
100% by intravenous route; not administered orally (bioavailability not applicable).
Intravenous: 100%.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of potassium and magnesium accumulation; use with caution and monitor electrolytes in moderate impairment (GFR 30-59 m L/min).
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No specific adjustment required; however, monitor electrolytes in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Dose based on weight and clinical status; typical initial infusion rate: 5-10 m L/kg/hour, adjusted based on response and electrolyte monitoring.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Use with caution due to reduced renal function; start at lower infusion rates (e.g., 50-100 m L/hour) and monitor for fluid overload and electrolyte disturbances.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
No black box warning is provided for this drug.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Use with caution in patients with heart failure, renal impairment, or conditions predisposing to fluid overload (e.g., congestive heart failure, pulmonary edema),Monitor electrolytes, fluid balance, and renal function during administration,Avoid in patients with hypervolemia, since this may exacerbate fluid overload conditions,Use with caution in patients receiving corticosteroids or corticotropin, as they may increase risk of fluid and electrolyte disturbances,Solutions containing acetate should be used with caution in patients with hepatic insufficiency
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Hypersensitivity to any component of the solution,Clinically significant hypervolemia (fluid overload),Hyperkalemia (for solutions containing potassium),Severe renal impairment (anuria or oliguria) unless dialysis is performed,Acute or chronic metabolic alkalosis (for solutions containing acetate)
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No specific food interactions; maintain normal diet unless otherwise directed by physician. Avoid excessive potassium-rich foods if renal impairment exists.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
No known teratogenic effects. Plasma-Lyte 56 is an electrolyte solution and does not cross placenta in significant amounts to cause fetal harm. Use if clearly needed.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Excreted into breast milk in negligible amounts; considered compatible with breastfeeding. M/P ratio not applicable as endogenous electrolytes.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No specific dose adjustments during pregnancy. Use standard dosing based on clinical status; avoid fluid overload in preeclampsia or cardiac conditions.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
Plasma-Lyte 56 is a balanced crystalloid solution containing acetate and gluconate as buffers, which may reduce the risk of hyperchloremic metabolic acidosis compared to 0.9% saline. It is isotonic (osmolarity 406 m Osm/L) but hypotonic in plasma due to metabolism of anions, making it suitable for maintenance fluid therapy. Use caution in patients with renal impairment due to potassium content (13 m Eq/L). Not for co-administration with blood products via same tubing due to calcium content (5 m Eq/L).
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This solution provides fluids and electrolytes to maintain hydration and balance.,It contains potassium; follow dietary restrictions if you have kidney problems.,Report any signs of fluid overload (swelling, shortness of breath) or electrolyte imbalances (muscle cramps, weakness, irregular heartbeat).,Do not eat or drink anything unless instructed by your healthcare provider during infusion.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 56 IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 56 IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by PLASMA-LYTE 56 is an isotonic crystalloid solution that provides electrolytes and water to maintain or restore intravascular volume and electrolyte balance. It expands extracellular fluid volume and improves circulation by increasing plasma volume. The solution's electrolyte composition mimics plasma, helping to correct electrolyte deficits and acid-base disturbances.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 56 IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 56 IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs; typical adult rate: 100-200 m L/hour.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 56 IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 56 IN PLASTIC CONTAINER is classified as Category C. No known teratogenic effects. Plasma-Lyte 56 is an electrolyte solution and does not cross placenta in significant amounts to cause fetal harm. Use if clearly needed.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.